BeiGene, Ltd. (BGNE) CMO Jane Huang Sells 1,600 Shares of Stock
BeiGene, Ltd. (NASDAQ:BGNE) CMO Jane Huang sold 1,600 shares of BeiGene stock in a transaction on Monday, November 20th. The stock was sold at an average price of $86.25, for a total transaction of $138,000.00. Following the sale, the chief marketing officer now directly owns 264,900 shares of the company’s stock, valued at approximately $22,847,625. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Jane Huang also recently made the following trade(s):
- On Thursday, November 16th, Jane Huang sold 600 shares of BeiGene stock. The shares were sold at an average price of $85.00, for a total transaction of $51,000.00.
Shares of BeiGene, Ltd. (NASDAQ:BGNE) opened at $84.87 on Tuesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33. BeiGene, Ltd. has a fifty-two week low of $26.43 and a fifty-two week high of $118.95.
BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Monday, November 13th. The company reported $2.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million during the quarter, compared to the consensus estimate of $1.55 million. During the same period in the prior year, the company earned ($1.08) earnings per share. equities research analysts forecast that BeiGene, Ltd. will post -3.09 EPS for the current year.
WARNING: “BeiGene, Ltd. (BGNE) CMO Jane Huang Sells 1,600 Shares of Stock” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/11/21/beigene-ltd-bgne-cmo-jane-huang-sells-1600-shares-of-stock.html.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new position in BeiGene in the 3rd quarter valued at approximately $160,000. Teachers Retirement System of The State of Kentucky bought a new position in shares of BeiGene during the third quarter valued at $248,000. SG Americas Securities LLC bought a new position in BeiGene during the second quarter worth $111,000. Aperio Group LLC bought a new position in BeiGene during the third quarter worth $301,000. Finally, Jane Street Group LLC bought a new position in BeiGene during the third quarter worth $339,000. Institutional investors and hedge funds own 57.07% of the company’s stock.
Several brokerages have recently issued reports on BGNE. Morgan Stanley reissued an “overweight” rating and issued a $95.00 price target (up previously from $87.00) on shares of BeiGene in a report on Friday, October 6th. Zacks Investment Research raised shares of BeiGene from a “hold” rating to a “buy” rating and set a $115.00 target price for the company in a research note on Tuesday, October 3rd. Maxim Group reaffirmed a “buy” rating and issued a $120.00 target price (up from $77.00) on shares of BeiGene in a research note on Thursday, September 28th. Cowen and Company reaffirmed a “buy” rating on shares of BeiGene in a research note on Tuesday, November 14th. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $83.00 target price (up from $58.00) on shares of BeiGene in a research note on Tuesday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $96.67.
BeiGene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.